Jaw-opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A.
We have reported a case series of five patients with jaw-opening oromandibular dystonia secondary to Wilson's disease (WD), in which the patients were treated with botulinum toxin type A (BTX-A). In all cases, dystonia score was partially reduced three weeks after injections. The most common side effect was transient mild dysphagia. This preliminary study showed that jaw-opening oromandibular dystonia in WD may be partially responsive to the use of BTX-A.
Neurology Service, Internal Medicine Department, Hospital de Clínicas, University of Paraná, Curitiba, PR, Brazil. hagteive@mps.com.br
Hélio A G
HA
Teive
Leandro E
LE
Klüppel
Renato P
RP
Munhoz
Nílson
N
Becker
Paulo R
PR
Müller
Lineu C
LC
Werneck
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006527:Hepatolenticular Degeneration / Q000150:complications*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008336:Mandibular Diseases / Q000188:drug therapy* / Q000209:etiology; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A